Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 168

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE‐mediated) asthma

Open access
Lowe, Philip J., Tannenbaum, Stacey, Gautier, Aurelie, Jimenez, Pablo · 2009 · British Journal of Clinical Pharmacology

Abstract

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • It had been hypothesized that there must be a relationship between free IgE concentrations and the signs and symptoms of asthma – after all, this is what drove the development of omalizumab. • However, although many statistical analyses of free IgE and spirometry data for patients equilibrated on omalizumab had shown a difference between placebo and treatment, no consistent time‐ and IgE‐dependent relationship had been shown due to the narrow range of free IgE being studied and the sparse nature of the sampling and clinical measurements in Phase III trials. WHAT THIS STUDY ADDS • The above problem was solved using a pharmacokinetic–pharmacodynamic (PK–PD) model to estimate free IgE concentrations for all time points throughout and after treatment with omalizumab, together with patient daily diary data. • This allowed for the first time the direct correlation between free IgE and signs and symptoms of asthma to be observed. • Doses and regimens for omalizumab could then be derived, through PK–PD model simulation, for suppressing free IgE to a point correlated with an improvement in clinical symptoms. AIMS: Omalizumab, a subcutaneously administered anti‐IgE antibody, is effective for moderate‐to‐severe persistent allergic asthma. The aims were to (i) describe the population pharmacodynamics of free IgE with a mechanism‐based, nonlinear, omalizumab–IgE binding model; (ii) deduce a target‐free IgE suppression level by correlation with clinical outcomes; and (iii) check the adequacy of current approved dosing tables and explore potential doses and regimens beyond. METHODS: Concentration data (omalizumab, free and total IgE) were obtained from 1781 patients aged 12–79 years, in four sparsely sampled randomized, placebo‐controlled studies and 152 subjects in a richly sampled single‐dose study. NONMEM predictive performance across the range of bodyweights (39–150 kg) and baseline IgE (19–1055 IU ml−1) was checked by simulation. Predicted free IgE levels were correlated with time‐averaged patient diary clinical outcomes. RESULTS: The model accurately predicted observed omalizumab, free and total IgE concentrations. Free IgE concentrations correlated well with clinical signs and symptoms, allowing a target concentration of 14 ng ml−1, at the midpoint of 4‐week clinical observation periods, to be set for determining the dose and regimen for omalizumab. CONCLUSIONS: The omalizumab–IgE binding model is predictive for free IgE and demonstrates a nonlinear time‐dependent relationship between free IgE suppression and clinical outcomes in asthma. Although currently approved dosing tables are close to optimal, it should be possible to treat patients with higher levels of baseline IgE if higher doses can be administered.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2125.2009.03401.x

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 168

Metadata

Authors
Lowe, P. J., Tannenbaum, S., Gautier, A., & Jimenez, P.
Venue
British Journal of Clinical Pharmacology
Publisher
Wiley
Published
2009-07
Volume
68
Issue
1
Pages
61-76
ISSN
  • 0306-5251 (ISSN-L)
  • 1365-2125
OpenAlex
W2164367822
Cited by
168
References
2
FWCI
7.09
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE‐mediated) asthma. https://app.cochat.ai/papers/10.1111/j.1365-2125.2009.03401.x
The paper
Lowe, P. J., Tannenbaum, S., Gautier, A., & Jimenez, P. (2009). Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE‐mediated) asthma. British Journal of Clinical Pharmacology. https://doi.org/10.1111/j.1365-2125.2009.03401.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.